Epidemiologist with the McMaster Evidence Review and Synthesis Team (MERST) at McMaster University in Hamilton, Ont.
Associate Professor in the School of Nursing at McMaster University and Lead of MERST.
Can Fam Physician. 2022 Jul;68(7):e215-e226. doi: 10.46747/cfp.6807e215.
To summarize evidence from published systematic reviews evaluating the effect of polypharmacy interventions on clinical and intermediate outcomes. It also summarizes the adverse events that may occur as a result of these interventions.
A literature search was conducted using the electronic databases MEDLINE, Embase, CINAHL, Cochrane Central, and Cochrane Database of Systematic Reviews (PROSPERO registration number: CRD42018085767).
The search yielded a total of 21,329 citations, of which 619 were reviewed as full text and 5 met the selection criteria.
The polypharmacy interventions were found to produce statistically significant reductions in potentially inappropriate prescribing and improved medication adherence; however, the observed effects on clinical and intermediate outcomes were inconsistent. None of the included reviews reported any significant benefit of polypharmacy interventions for quality-of-life outcomes. Specific to health care utilization and cost, polypharmacy interventions reduced health care resource usage and expenditure. The reviews reported no differences in adverse drug events between polypharmacy interventions and usual care groups. The overall certainty of evidence was reported as low to very low across included reviews.
Polypharmacy interventions are associated with reductions in potentially inappropriate prescribing and improvements in medication adherence. However, there is limited evidence of their effectiveness for clinical and intermediate outcomes.
总结已发表的系统评价文献,评估多种药物治疗干预对临床和中间结局的影响。还总结了这些干预可能导致的不良事件。
使用电子数据库 MEDLINE、Embase、CINAHL、Cochrane 中心和 Cochrane 系统评价数据库(PROSPERO 注册号:CRD42018085767)进行文献检索。
检索共产生了 21329 条引文,其中 619 条被作为全文进行了回顾,5 条符合入选标准。
多种药物治疗干预被发现可显著减少潜在不适当的处方和提高药物依从性;然而,对临床和中间结局的观察效果不一致。纳入的综述均未报告多种药物治疗干预对生活质量结局有任何显著益处。具体到医疗保健的使用和成本,多种药物治疗干预减少了医疗保健资源的使用和支出。综述报告,多种药物治疗干预组与常规护理组之间在药物不良事件方面无差异。纳入的综述报告证据总体确定性为低至极低。
多种药物治疗干预与潜在不适当处方的减少和药物依从性的提高有关。然而,其对临床和中间结局的有效性证据有限。